Brooklyn Investment Group Acquires 3,033 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Brooklyn Investment Group increased its holdings in Gilead Sciences, Inc. by 50.9% during Q1, now owning 8,986 shares valued at over $1 million.
• Gilead Sciences reported $2.01 earnings per share for the latest quarter, surpassing estimates, with quarterly revenue of $7.08 billion.
• The company declared a quarterly dividend of $0.79 per share, reflecting an annualized yield of 2.7%, to be paid on September 29th.

Brooklyn Investment Group grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 50.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,986 shares of the biopharmaceutical company's stock after purchasing an additional 3,033 shares during the period. Brooklyn Investment Group's holdings in Gilead Sciences were worth $1,007,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Redwood Financial Network Corp increased its position in Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after purchasing an additional 98 shares during the period. Argentarii LLC increased its position in Gilead Sciences by 3.0% during the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after purchasing an additional 99 shares during the period. Peak Financial Advisors LLC increased its position in Gilead Sciences by 1.7% during the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock valued at $677,000 after purchasing an additional 100 shares during the period. Perkins Coie Trust Co increased its position in Gilead Sciences by 2.6% during the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after purchasing an additional 100 shares during the period. Finally, Investment Research & Advisory Group Inc. increased its position in Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 100 shares during the period. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. Oppenheimer dropped their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a report on Friday, July 25th. Morgan Stanley boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a report on Friday, August 8th. Finally, Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $115.39.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the sale, the director directly owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the sale, the chief financial officer directly owned 160,110 shares of the company's stock, valued at $18,977,838.30. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,339,230 over the last 90 days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

GILD traded down $1.37 during midday trading on Friday, hitting $114.77. 5,481,103 shares of the company traded hands, compared to its average volume of 8,276,482. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $142.41 billion, a PE ratio of 22.86, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. The company's 50-day moving average is $112.41 and its 200 day moving average is $108.90. Gilead Sciences, Inc. has a 52 week low of $75.91 and a 52 week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio is presently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.